JP5710246B2 - 診断用画像及び放射線治療用の葉酸複合体及び対応する金属キレート錯体 - Google Patents

診断用画像及び放射線治療用の葉酸複合体及び対応する金属キレート錯体 Download PDF

Info

Publication number
JP5710246B2
JP5710246B2 JP2010502521A JP2010502521A JP5710246B2 JP 5710246 B2 JP5710246 B2 JP 5710246B2 JP 2010502521 A JP2010502521 A JP 2010502521A JP 2010502521 A JP2010502521 A JP 2010502521A JP 5710246 B2 JP5710246 B2 JP 5710246B2
Authority
JP
Japan
Prior art keywords
alkyl
independently
substituted
hal
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010502521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523626A5 (enExample
JP2010523626A (ja
Inventor
モーザー・ルードルフ
シブリ・ロジャー
ミュラー・クリスティーナ・マクダレーナ
グレーン・ヴィーオラ
ミヒェル・ウルス
シュパル・クリストフ
ミント・トーマス・ライクトン
Original Assignee
メルク エ カンパニー
メルク エ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク エ カンパニー, メルク エ カンパニー filed Critical メルク エ カンパニー
Publication of JP2010523626A publication Critical patent/JP2010523626A/ja
Publication of JP2010523626A5 publication Critical patent/JP2010523626A5/ja
Application granted granted Critical
Publication of JP5710246B2 publication Critical patent/JP5710246B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/22—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by measuring secondary emission from the material
    • G01N23/2204—Specimen supports therefor; Sample conveying means therefore
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Radiation-Therapy Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2010502521A 2007-04-11 2008-04-11 診断用画像及び放射線治療用の葉酸複合体及び対応する金属キレート錯体 Expired - Fee Related JP5710246B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07105980.2 2007-04-11
EP07105980 2007-04-11
PCT/EP2008/054409 WO2008125618A1 (en) 2007-04-11 2008-04-11 Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014099667A Division JP5876527B2 (ja) 2007-04-11 2014-05-13 診断用画像及び放射線治療用の葉酸複合体及び対応する金属キレート錯体

Publications (3)

Publication Number Publication Date
JP2010523626A JP2010523626A (ja) 2010-07-15
JP2010523626A5 JP2010523626A5 (enExample) 2014-01-16
JP5710246B2 true JP5710246B2 (ja) 2015-04-30

Family

ID=39683755

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010502521A Expired - Fee Related JP5710246B2 (ja) 2007-04-11 2008-04-11 診断用画像及び放射線治療用の葉酸複合体及び対応する金属キレート錯体
JP2014099667A Expired - Fee Related JP5876527B2 (ja) 2007-04-11 2014-05-13 診断用画像及び放射線治療用の葉酸複合体及び対応する金属キレート錯体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014099667A Expired - Fee Related JP5876527B2 (ja) 2007-04-11 2014-05-13 診断用画像及び放射線治療用の葉酸複合体及び対応する金属キレート錯体

Country Status (11)

Country Link
US (2) US20100143249A1 (enExample)
EP (1) EP2146995A1 (enExample)
JP (2) JP5710246B2 (enExample)
KR (2) KR20150140415A (enExample)
CN (1) CN101646672B (enExample)
AU (1) AU2008237935B2 (enExample)
CA (1) CA2670385C (enExample)
EA (1) EA200901344A1 (enExample)
IL (1) IL201250A0 (enExample)
WO (1) WO2008125618A1 (enExample)
ZA (1) ZA200903483B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150140415A (ko) * 2007-04-11 2015-12-15 메르크 앤드 씨에 진단 이미징 및 방사선치료에 사용하기 위한 폴레이트-컨쥬게이트 및 대응하는 금속-킬레이트 착물
US8236284B1 (en) * 2008-04-02 2012-08-07 University Of Central Florida Research Foundation, Inc. Multimodal, multifunctional polymer coated nanoparticles
FR2942227B1 (fr) * 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
WO2011084571A2 (en) 2009-12-16 2011-07-14 Mallinckrodt Inc. Azide derivatives for phototherapy
PT2766364T (pt) * 2011-08-17 2024-09-24 Merck & Cie Conjugados de folato de entidades de ligação a albumina
AU2013258027B2 (en) 2012-05-08 2017-11-30 Merck & Cie 18F-labelled follate/antifolate analogues
JP2018504422A (ja) * 2015-02-06 2018-02-15 センプラ ファーマシューティカルズ，インコーポレイテッド ４−アジドブチルアミンおよびその調製方法
WO2020256210A1 (ko) 2019-06-20 2020-12-24 주식회사 쿼드마이너 네트워크 포렌식 시스템 및 이를 이용한 네트워크 포렌식 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
EP1389209B1 (en) * 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
ES2500922T3 (es) * 2002-05-06 2014-10-01 Endocyte, Inc. Agentes de formación de imágenes dirigidos al receptor de folato
AU2004235488A1 (en) * 2003-04-29 2004-11-11 Universitat Zurich Nepsilon and/or nalpha derivatized, metal and organic protected l-histidine for coupling to biomolecules for highly efficient labeling with [M(OH2)3(CO)3]+ by fac coordination
US9265746B2 (en) * 2006-05-31 2016-02-23 Merck & Cie Method for cell-specific targeting
KR20150140415A (ko) * 2007-04-11 2015-12-15 메르크 앤드 씨에 진단 이미징 및 방사선치료에 사용하기 위한 폴레이트-컨쥬게이트 및 대응하는 금속-킬레이트 착물

Also Published As

Publication number Publication date
WO2008125618A1 (en) 2008-10-23
CA2670385A1 (en) 2008-10-23
CN101646672B (zh) 2015-08-19
EA200901344A1 (ru) 2010-04-30
US20170128599A1 (en) 2017-05-11
AU2008237935A1 (en) 2008-10-23
CN101646672A (zh) 2010-02-10
CA2670385C (en) 2016-01-12
ZA200903483B (en) 2010-04-28
EP2146995A1 (en) 2010-01-27
JP2014193889A (ja) 2014-10-09
IL201250A0 (en) 2010-05-31
KR20150140415A (ko) 2015-12-15
AU2008237935B2 (en) 2014-03-27
HK1138571A1 (zh) 2010-08-27
US20100143249A1 (en) 2010-06-10
KR20100016330A (ko) 2010-02-12
KR101605426B1 (ko) 2016-03-22
JP2010523626A (ja) 2010-07-15
JP5876527B2 (ja) 2016-03-02

Similar Documents

Publication Publication Date Title
JP5876527B2 (ja) 診断用画像及び放射線治療用の葉酸複合体及び対応する金属キレート錯体
KR101639268B1 (ko) １８ ｆ-표지된 폴레이트
JP6198814B2 (ja) １８ｆ標識された葉酸／葉酸代謝拮抗物質同族体
US9771368B2 (en) 18F-labelled folates
CN102177160B (zh) 作为pet放射性示踪剂的18f-标记叶酸
HK1138571B (en) Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy
HK1175169A (en) 18f-labelled folates
HK1139129B (en) 18f-labelled folates

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110330

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130820

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130920

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130930

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20131119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140114

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20140303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140513

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140916

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150304

R150 Certificate of patent or registration of utility model

Ref document number: 5710246

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees